RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

REGENXBIO Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$7.15+0.23 (+3.25%)

Close on Oct 19, 2026

Market cap: $379.06M
P/E (TTM): –
Dividend yield: –

REGENXBIO Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Depreciation & Amortization	16	16	17	13	9.56	8.41	7.15	3.98	2.69	0.54	0.08	0	0
Stock-Based Compensation	35	38	40	41	39	32	27	17	11	7.03	2.92	0.32	–
Deferred Income Taxes	–	–	–	–	–	–	-0.47	–	–	-0.44	–	–	–
Other Non-Cash Items	-0.60	-1.32	-0.32	-0.23	0.28	-0.16	-0.27	-0.01	-0.07	0.40	-0.02	-0.18	–
Change in Accounts Receivable	-7.66	9.71	3.94	4.82	14	-9.90	-8.62	-17	0.56	1.07	-0.27	-0.84	-0.04
Change in Accounts Payable	-2.28	-0.29	-2.79	19	-2.30	3.87	1.53	-0.22	2.62	0.19	0.59	0.03	0.26
Change in Unearned Revenue	29	-0.03	-1.51	-1.17	-0.90	–	-0.60	3.93	–	–	–	–	–
Operating Cash Flow	-124	-173	-218	-207	219	-54	-108	105	-58	-49	-23	-2.40	-3.01
Capital Expenditures	-2.41	-2.44	-9.96	-31	-84	-27	-12	-13	-7.16	-8.15	-0.52	–	–
Purchase of Investments	-333	-190	-87	-185	-498	-123	-191	-446	-69	-45	-163	–	–
Sale & Maturity of Investments	319	290	285	203	170	233	290	180	70	73	–	–	–
Investing Cash Flow	-16	103	191	-12	-407	123	94	-279	-4.79	19	-164	–	–
Stock Issued	–	–	–	–	–	–	–	190	82	–	–	–	–
Financing Cash Flow	117	93	-35	-29	195	200	8.38	204	85	0.12	239	2.40	1.97
Net Change in Cash	-23	23	-62	-248	7.48	269	-5.77	30	22	-29	53	0.00	-1.05
Free Cash Flow	-126	-176	-228	-238	135	-81	-119	91	-65	-57	-23	–	–
Income Taxes Paid	0.29	-0.07	-0.14	12	6.00	-0.19	0.90	3.44	–	–	–	–	–
Interest Paid	–	–	–	–	–	–	–	–	–	–	0.01	0.16	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -94.1%
Net margin: -112.6%
Return on equity, FY2025: -107.0%

Financial strength

Current ratio: 2.86
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 44.2%

Valuation

P/E ratio: –
Price to sales: 2.17
Price to book: 5.28
Dividend yield: –